Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
03:51pm, Thursday, 08'th May 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
10:35am, Thursday, 08'th May 2025
Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
09:35am, Wednesday, 07'th May 2025
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript
11:35pm, Tuesday, 06'th May 2025
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - CO
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:35pm, Tuesday, 06'th May 2025
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
06:40pm, Tuesday, 06'th May 2025
Myriad Genetics (MYGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago.
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
04:05pm, Tuesday, 06'th May 2025
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year.
Myriad Genetics: Significantly Undervalued With Profitability In Sight
12:58am, Friday, 02'nd May 2025
Initiate Buy on Myriad Genetics, trading near multi-year lows with potential for significant growth driven by new offerings and stable core franchises. Strong financials with $158 million in liquidity
More than half say genetic testing for mental health medications could reduce concerns More than half say genetic testing for mental health medications could reduce concerns
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
04:05pm, Friday, 25'th Apr 2025
Podium presentation showcases the clinical application of Precise™ MRD Podium presentation showcases the clinical application of Precise™ MRD
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
11:10am, Tuesday, 22'nd Apr 2025
In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. Accor
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical
Myriad Genetics Announces Inducement Awards
04:15pm, Tuesday, 08'th Apr 2025
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
08:00am, Monday, 07'th Apr 2025
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donn
